Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 10;5(1):9.
doi: 10.1186/s43556-024-00170-6.

mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma

Lincheng Zhang #  1   2   3 , Peng Liu #  4   5 , Li Zhuang #  6 , Sunbin Ling  7 , Qifan Zhan  1   2 , Wei Zhou  1   2 , Renyi Su  1   2 , Lu Yin  2 , Qingyang Que  1   2 , Jiachen Hong  8 , Jiaqi Bao  9 , Chuxiao Shao  10 , Jinzhen Cai  11   12 , Shusen Zheng  13   14 , Xiao Xu  15   16   17
Affiliations

mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma

Lincheng Zhang et al. Mol Biomed. .

Abstract

Sirolimus is a regularly applied immunosuppressant for patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Sirolimus not only significantly inhibits HCC recurrence but also protects renal function. However, the improvement effect of sirolimus on nontumour-related death in patients is still unknown. The aim of our study was to investigate the therapeutic effect of sirolimus on nontumour-related deaths. In this study, we retrospectively enrolled 403 LT patients with HCC from January 1, 2015, to December 31, 2018. The median follow-up time was 47.1 months. The patients were divided into the sirolimus group (N = 184) and the sirolimus-free group (N = 219). There were no significant differences between the sirolimus group and the sirolimus-free group in survival (P = 0.054). In transplant patients who exceeded the Milan or Hangzhou criteria, the sirolimus group achieved higher survival than the sirolimus-free group (P = 0.005; P = 0.02). Moreover, multivariate analysis showed that sirolimus strongly reduced the hazard ratio (HR) for nontumour-related death in LT patients who exceeded the Milan (HR: 0.42; 95% CI: 0.18-1; P = 0.05) or Hangzhou criteria (HR: 0.26; 95% CI: 0.08-0.89; P = 0.032). HCC recurrence increased the risk of nontumour-related death. In conclusion, sirolimus-based immunosuppression can significantly reduce nontumour-related death in LT patients who exceed the criteria for transplantation. In addition, this finding will further promote the application of sirolimus after liver transplantation for hepatocellular carcinoma.

Keywords: Hepatocellular carcinoma; Liver transplantation; Nontumour-related death; Sirolimus.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Flowchart for screening patients
Fig. 2
Fig. 2
Comparison of survival between the sirolimus group (N = 184) and sirolimus-free group (N = 219) among all patients (P = 0.054)
Fig. 3
Fig. 3
Comparison of survival between the sirolimus group (N = 96) and sirolimus-free group (N = 109) among patients fulfilling the Milan criteria (P = 0.78) (a). Comparison of survival between the sirolimus group (N = 88) and sirolimus-free group (N = 110) among patients exceeding the Milan criteria (P = 0.005) (b). The distribution of causes of death in patients exceeding the Milan criteria was distinguished by sirolimus administration (c)
Fig. 4
Fig. 4
Comparison of survival between the sirolimus group (N = 141) and sirolimus-free group (N = 166) among patients fulfilling the Hangzhou criteria (P = 0.3) (a). Comparison of survival between the sirolimus group (N = 43) and sirolimus-free group (N = 53) among patients exceeding the Hangzhou criteria (P = 0.02) (b). The distribution of causes of death in patients exceeding the Hangzhou criteria was distinguished by sirolimus administration (c)
Fig. 5
Fig. 5
Comparison of survival between patients with (N = 130) and without hepatocellular carcinoma recurrence (N = 273) (P < 0.0001) (a). Distribution of causes of death, recurrence vs. nonrecurrence group (b)
See this image and copyright information in PMC

Similar articles

  • A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. Schnitzbauer AA, et al. BMC Cancer. 2010 May 11;10:190. doi: 10.1186/1471-2407-10-190. BMC Cancer. 2010. PMID: 20459775 Free PMC article. Clinical Trial.
  • Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ. Geissler EK, et al. Transplantation. 2016 Jan;100(1):116-25. doi: 10.1097/TP.0000000000000965. Transplantation. 2016. PMID: 26555945 Free PMC article. Clinical Trial.
  • mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
    Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, Geissler EK. Schnitzbauer AA, et al. Ann Surg. 2020 Nov;272(5):855-862. doi: 10.1097/SLA.0000000000004280. Ann Surg. 2020. PMID: 32889867 Clinical Trial.
  • mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
    Duvoux C, Toso C. Duvoux C, et al. Transplant Rev (Orlando). 2015 Jul;29(3):168-74. doi: 10.1016/j.trre.2015.02.003. Epub 2015 Feb 25. Transplant Rev (Orlando). 2015. PMID: 26071984 Review.
  • Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Grigg SE, et al. Aliment Pharmacol Ther. 2019 May;49(10):1260-1273. doi: 10.1111/apt.15253. Epub 2019 Apr 15. Aliment Pharmacol Ther. 2019. PMID: 30989721
See all similar articles

Cited by

References

    1. Line PD. Frontiers in liver transplantation. Br J Surg. 2020;107(7):790–792. doi: 10.1002/bjs.11714. - DOI - PubMed
    1. Li J, Zhou J-K, Mu X, Shen S, Xu X, Luo Y, et al. Regulation of XPO5 phosphorylation by PP2A in hepatocellular carcinoma. MedComm. 2022;3(2):e125. doi: 10.1002/mco2.125. - DOI - PMC - PubMed
    1. Li S, Liu R, Pan Q, Wang G, Cheng D, Yang J, et al. De novo lipogenesis is elicited dramatically in human hepatocellular carcinoma especially in hepatitis C virus-induced hepatocellular carcinoma. MedComm. 2020;1(2):178–187. doi: 10.1002/mco2.15. - DOI - PMC - PubMed
    1. Ling S, Jiang G, Que Q, Xu S, Chen J, Xu X. Liver transplantation in patients with liver failure: Twenty years of experience from China. Liver Int. 2022;42(9):2110–2116. doi: 10.1111/liv.15288. - DOI - PubMed
    1. Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65(6):1035–1041. doi: 10.1136/gutjnl-2014-308513. - DOI - PMC - PubMed

Publication types

MeSH terms